TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $108.23 million. The enterprise value is $101.75 million.
| Market Cap | 108.23M |
| Enterprise Value | 101.75M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 24.65 million shares outstanding. The number of shares has increased by 40.58% in one year.
| Shares Outstanding | 24.65M |
| Shares Change (YoY) | +40.58% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | 86.85% |
| Float | 15.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.85 |
| Forward PS | 1.42 |
| PB Ratio | 5.73 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.23, with a Debt / Equity ratio of 2.15.
| Current Ratio | 4.23 |
| Quick Ratio | 3.34 |
| Debt / Equity | 2.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.93 |
Financial Efficiency
Return on equity (ROE) is -201.60% and return on invested capital (ROIC) is -74.21%.
| Return on Equity (ROE) | -201.60% |
| Return on Assets (ROA) | -58.60% |
| Return on Capital (ROIC) | -74.21% |
| Revenue Per Employee | $257,502 |
| Profits Per Employee | -$205,568 |
| Employee Count | 227 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.25% in the last 52 weeks. The beta is 0.95, so TELA Bio's price volatility has been similar to the market average.
| Beta (1Y) | 0.95 |
| 52-Week Price Change | -53.25% |
| 50-Day Moving Average | 5.74 |
| 200-Day Moving Average | 6.93 |
| Relative Strength Index (RSI) | 30.45 |
| Average Volume (30 Days) | 126,245 |
Short Selling Information
The latest short interest is 925,979, so 3.76% of the outstanding shares have been sold short.
| Short Interest | 925,979 |
| Short Previous Month | 786,235 |
| Short % of Shares Out | 3.76% |
| Short % of Float | 5.87% |
| Short Ratio (days to cover) | 5.98 |
Income Statement
In the last 12 months, TELA Bio had revenue of $58.45 million and -$46.66 million in losses. Loss per share was -$2.04.
| Revenue | 58.45M |
| Gross Profit | 40.11M |
| Operating Income | -44.08M |
| Pretax Income | -46.66M |
| Net Income | -46.66M |
| EBITDA | -40.63M |
| EBIT | -41.44M |
| Loss Per Share | -$2.04 |
Balance Sheet
The company has $46.99 million in cash and $40.52 million in debt, giving a net cash position of $6.48 million or $0.26 per share.
| Cash & Cash Equivalents | 46.99M |
| Total Debt | 40.52M |
| Net Cash | 6.48M |
| Net Cash Per Share | $0.26 |
| Equity / Book Value | 18.88M |
| Book Value Per Share | 0.77 |
| Working Capital | 54.76M |
Cash Flow
In the last 12 months, operating cash flow was -$40.86 million and capital expenditures -$599,000, giving a free cash flow of -$41.46 million.
| Operating Cash Flow | -40.86M |
| Capital Expenditures | -599,000 |
| Free Cash Flow | -41.46M |
| FCF Per Share | -$1.81 |
Margins
Gross margin is 68.62%, with operating and profit margins of -75.40% and -79.83%.
| Gross Margin | 68.62% |
| Operating Margin | -75.40% |
| Pretax Margin | -79.83% |
| Profit Margin | -79.83% |
| EBITDA Margin | -69.51% |
| EBIT Margin | -70.90% |
| FCF Margin | -70.92% |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.58% |
| Shareholder Yield | -40.58% |
| Earnings Yield | -43.12% |
| FCF Yield | -38.30% |
Analyst Forecast
The average price target for TELA Bio is $13.67, which is 211.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.67 |
| Price Target Difference | 211.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 30.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -4.82 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.82 |
| Piotroski F-Score | 3 |